IBRX
The money part is getting loud
ImmunityBio just dropped a Q2 update that sounds a lot less like “early-stage biotech” and a lot more like “commercial business with momentum.” Net product revenue hit a record $50.7 million, up 92% year over year and 15% from Q1.
That matters because biotech investors usually live in a world of future tense. Revenue like this is one of the few times the company can point to real receipts and say, “No, seriously, the product is selling.”
Why investors are paying attention
The company also said first-half revenue jumped 121% to $94.8 million. That’s the kind of growth curve that can make a stock market sit up a little straighter, especially when it comes alongside ongoing regulatory and clinical progress across the pipeline.
In other words:
- sales are growing fast,
- the business is getting more commercial traction,
- and the pipeline still has catalysts to keep the story alive.
The biotech version of a glow-up
This doesn’t mean the whole movie is over. Biotech is still biotech, which is basically the financial version of waiting for a plot twist in the final five minutes. But if ImmunityBio can keep stacking revenue growth on top of pipeline wins, the stock has a much more credible story to tell.
Big picture: investors tend to like two things at once — real sales and future upside. ImmunityBio is trying to hand them both in the same quarter.